Roth Capital Predicts GeoVax Labs FY2029 Earnings

GeoVax Labs, Inc. (NASDAQ:GOVX) – Analysts at Roth Capital issued their FY2029 earnings per share (EPS) estimates for shares of GeoVax Labs in a research report issued on Friday, March 28th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings per share of $12.20 for the year. The consensus estimate for GeoVax Labs’ current full-year earnings is ($4.49) per share.

Separately, D. Boral Capital reissued a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research note on Friday. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Trading Down 12.6 %

NASDAQ:GOVX opened at $1.11 on Monday. The company has a 50-day moving average price of $1.67 and a 200-day moving average price of $2.13. The stock has a market cap of $10.47 million, a price-to-earnings ratio of -0.20 and a beta of 3.06. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.38 million.

Institutional Trading of GeoVax Labs

A number of hedge funds have recently modified their holdings of GOVX. Citadel Advisors LLC bought a new position in shares of GeoVax Labs in the 4th quarter worth about $104,000. Virtu Financial LLC purchased a new stake in GeoVax Labs in the third quarter worth about $97,000. Geode Capital Management LLC increased its stake in shares of GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares in the last quarter. Finally, Northern Trust Corp purchased a new position in shares of GeoVax Labs during the fourth quarter valued at approximately $29,000. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.